Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu vaccine showdown: which shot protects seniors best?

NCT ID NCT06029933

Prevention Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study compares two flu vaccines—Fluad and Fluzone High-Dose—in adults aged 65 and older to see which is more effective at preventing lab-confirmed flu and related complications like pneumonia or heart issues. Researchers will look at health records from over a million seniors across several flu seasons. The goal is to find out if one vaccine offers better protection for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adjuvanted quadrivalent inactivated influenza vaccine (Fluad) compared with high-dose quadrivalent inactivated influenza vaccine (Fluzone High-Dose)
What this could lead to
If one vaccine proves more effective, it could guide flu shot recommendations for older adults, potentially reducing flu-related hospitalizations and complications.
What could go wrong
This is an observational study, so results may be influenced by factors other than the vaccines themselves. Also, flu seasons vary, so findings may not apply to all years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes KPNC adults ≥65 years who receive Fluad or Fluzone High-Dose influenza vaccine as part of routine clinical care during the 2023/24, 2024/25, and/or 2026/27 influenza seasons.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥65 years at the time of influenza vaccination * KPNC member at the time of vaccination * Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons Exclusion Criteria: * Age \<65 years at the time of influenza vaccination * Received either aIIV4 or HD-IIV4 in the inpatient setting * Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons) * Receive an influenza vaccination outside of KPNC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular events are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumonia influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular events Community-acquired pneumonia Influenza

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kaiser Permanente Northern California (entire region)

    RECRUITING

    Oakland, California, 94612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.